Public-registry trials using NX9 Oral Contrast Agent that Eichor's radar has found — 1 trial. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| Phase 2 Study of NX9 for Delineation of Bowel Anatomy | Nextrast, Inc. | GI Carcinoma | PHASE2 | 2 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →